

Psychische Störungen und Palliative Care

Troubles psychiques et soins palliatifs

Literatur / Références

1. Ita, D., M. Keorney, and L. O'Slorain, Psychiatric disorder in a palliative care unit. *Palliat Med*, 2003. 17(2): p. 212–8.
2. Mitchell, A.J., et al., Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. *Lancet Oncol*, 2011. 12(2): p. 160–74.
3. Akechi, T., et al., Psychiatric disorders in cancer patients: descriptive analysis of 1721 psychiatric referrals at two Japanese cancer center hospitals. *Jpn J Clin Oncol*, 2001. 31(5): p. 188–94.
4. Miovic, M. and S. Block, Psychiatric disorders in advanced cancer. *Cancer*, 2007. 110(8): p. 1665–76.
5. Ruggeri, M., et al., Definition and prevalence of severe and persistent mental illness. *Br J Psychiatry*, 2000. 177: p. 149–55.
6. Woods, A., et al., Palliative care for people with severe persistent mental illness: a review of the literature. *Can J Psychiatry*, 2008. 53(11): p. 725–36.
7. Colton, C.W. and R.W. Manderscheid, Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. *Prev Chronic Dis*, 2006. 3(2): p. A42.
8. Miller, B.J., C.B. Paschall, 3rd, and D.P. Svendsen, Mortality and medical comorbidity among patients with serious mental illness. *Psychiatr Serv*, 2006. 57(10): p. 1482–7.
9. Felker, B., J.J. Yazel, and D. Short, Mortality and medical comorbidity among psychiatric patients: a review. *Psychiatr Serv*, 1996. 47(12): p. 1356–63.
10. Iacovides, A. and M. Siamouli, Comorbid mental and somatic disorders: an epidemiological perspective. *Curr Opin Psychiatry*, 2008. 21(4): p. 417–21.
11. Steinhausen, H.C., The outcome of anorexia nervosa in the 20th century. *Am J Psychiatry*, 2002. 159(8): p. 1284–93.
12. Keel, P.K., et al., Predictors of mortality in eating disorders. *Arch Gen Psychiatry*, 2003. 60(2): p. 179–83.
13. Dein, S., Psychiatric liaison in palliative care. *Advances in Psychiatric Treatment*, 2003. 9: p. 241–248.
14. Satin, J.R., W. Linden, and M.J. Phillips, Depression as a predictor of disease progression and mortality in cancer patients: a meta-analysis. *Cancer*, 2009. 115(22): p. 5349–61.
15. Chochinov, H.M., et al., Prevalence of depression in the terminally ill: effects of diagnostic criteria and symptom threshold judgments. *Am J Psychiatry*, 1994. 151(4): p. 537–40.
16. Warmenhoven, F., et al., How family physicians address diagnosis and management of depression in palliative care patients. *Ann Fam Med*, 2012. 10(4): p. 330–6.
17. Chochinov, H.M., et al., "Are you depressed?" Screening for depression in the terminally ill. *Am J Psychiatry*, 1997. 154(5): p. 674–6.
18. Passik, S.D., Supportive care of the patient with pancreatic cancer: role of the psycho-oncologist. *Oncology (Williston Park)*, 1996. 10(9 Suppl): p. 33–4.
19. Lynch, M.E., The assessment and prevalence of affective disorders in advanced cancer. *J Palliat Care*, 1995. 11(1): p. 10–8.
20. Trask, P.C., Assessment of depression in cancer patients. *J Natl Cancer Inst Monogr*, 2004(32): p. 80–92.
21. Olden, M., et al., Measuring depression at the end of life: is the Hamilton Depression Rating Scale a valid instrument? *Assessment*, 2009. 16(1): p. 43–54.
22. Lloyd-Williams, M., C. Shiels, and C. Dowrick, The development of the Brief Edinburgh Depression Scale (BEDS) to screen for depression in patients with advanced cancer. *J Affect Disord*, 2007. 99(1–3): p. 259–64.
23. Bergant, A.M., et al., [German language version and validation of the Edinburgh postnatal depression scale]. *Dtsch Med Wochenschr*, 1998. 123(3): p. 35–40.
24. Lloyd-Williams, M., T. Friedman, and N. Rudd, Criterion validation of the Edinburgh postnatal depression scale as a screening tool for depression in patients with advanced metastatic cancer. *J Pain Symptom Manage*, 2000. 20(4): p. 259–65.
25. Kissane, D.W., et al., The Demoralization Scale: a report of its development and preliminary validation. *J Palliat Care*, 2004. 20(4): p. 269–76.

26. de Figueiredo, J.M., Depression and demoralization: phenomenologic differences and research perspectives. *Compr Psychiatry*, 1993. 34(5): p. 308–11.
27. Chochinov, H.M., et al., Desire for death in the terminally ill. *Am J Psychiatry*, 1995. 152(8): p. 1185–91.
28. O'Mahony, S., et al., Desire for hastened death, cancer pain and depression: report of a longitudinal observational study. *J Pain Symptom Manage*, 2005. 29(5): p. 446–57.
29. Breitbart, W., et al., Depression, hopelessness, and desire for hastened death in terminally ill patients with cancer. *JAMA*, 2000. 284(22): p. 2907–11.
30. Rosenstein, D.L., Depression and end-of-life care for patients with cancer. *Dialogues Clin Neurosci*, 2011. 13(1): p. 101–8.
31. Holsboer-Trachsler, E.H., J; Beck, J; Brand, S; Hemmeter, UM; Keck, ME, Rennhard, S; Hatzinger, M; Merlo, M; Bondolfi, G; Preisig, M; Attinger Andreoli, Y; Gehret, A; Bielinski, D, Seifritz, E, Die somatische Behandlung der unipolaren depressiven Störung. *Schweizerisches Medizin-Forum*, 2010. 10(46): p. 802–809.
32. Portela, M.A., A.S. Rubiales, and C. Centeno, The use of psychostimulants in cancer patients. *Curr Opin Support Palliat Care*, 2011. 5(2): p. 164–8.
33. Irwin, S.A. and A. Iglewicz, Oral ketamine for the rapid treatment of depression and anxiety in patients receiving hospice care. *J Palliat Med*, 2010. 13(7): p. 903–8.
34. Nubling, G., S. Allmendinger, and S. Lorenzl, [Drug therapy of anxiety and fear in palliative care patients with cancer or other illnesses: a systematic review]. *Schmerz*, 2012. 26(5): p. 537–49.
35. Keck, M.R., A; Rufer, M; Hemmeter, UM; Bondolfi, G; Preisig, M; Rennhard, S; Hatzinger, M; Holsboer-Trachsler, E; Hättenschwiler, J.; Seifritz, E., Die Behandlung der Angsterkrankungen. *Schweizerisches Medizin-Forum*, 2011. 11(34): p. 558–566.
36. Jackson, K.C. and A.G. Lipman, Drug therapy for anxiety in palliative care. *Cochrane Database Syst Rev*, 2004(1): p. CD004596.
37. Grob, C.S., et al., Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. *Arch Gen Psychiatry*, 2011. 68(1): p. 71–8.
38. Holland, J.C., et al., A randomized clinical trial of alprazolam versus progressive muscle relaxation in cancer patients with anxiety and depressive symptoms. *J Clin Oncol*, 1991. 9(6): p. 1004–11.
39. Horvath, A.O. and L. Luborsky, The role of the therapeutic alliance in psychotherapy. *J Consult Clin Psychol*, 1993. 61(4): p. 561–73.
40. Wilson, K.G., et al., Structured interview assessment of symptoms and concerns in palliative care. *Can J Psychiatry*, 2004. 49(6): p. 350–8.
41. Chochinov, H.M., et al., Dignity therapy: a novel psychotherapeutic intervention for patients near the end of life. *J Clin Oncol*, 2005. 23(24): p. 5520–5.
42. Chochinov, H.M., et al., Effect of dignity therapy on distress and end-of-life experience in terminally ill patients: a randomised controlled trial. *Lancet Oncol*, 2011. 12(8): p. 753–62.
43. Breitbart, W. and Y. Alici, Agitation and delirium at the end of life: "We couldn't manage him". *JAMA*, 2008. 300(24): p. 2898–910, E1.
44. Spiller, J.A. and J.C. Keen, Hypoactive delirium: assessing the extent of the problem for inpatient specialist palliative care. *Palliat Med*, 2006. 20(1): p. 17–23.
45. Hasemann, W., et al., [Delirium: screening, assessment and diagnosis]. *Pflege*, 2007. 20(4): p. 191–204.
46. Caraceni A, G.G., Delirium – Acute confusional states in palliative medicine. 2nd ed. 2011, Oxford: Oxford University Press. 275.
47. Morita, T., et al., Family-perceived distress from delirium-related symptoms of terminally ill cancer patients. *Psychosomatics*, 2004. 45(2): p. 107–13.
48. Lawlor, P.G., R.L. Fainsinger, and E.D. Bruera, Delirium at the end of life: critical issues in clinical practice and research. *JAMA*, 2000. 284(19): p. 2427–9.
49. Perrar, K.M.G., H.; Voltz, R., Verwirrtheit – Das delirante Syndrom in der Palliativmedizin. *Z Palliativmedizin*, 2012. 13: p. 177–190.
50. Bruera, E., et al., Cognitive failure in patients with terminal cancer: a prospective study. *J Pain Symptom Manage*, 1992. 7(4): p. 192–5.
51. Lawlor, P.G., et al., Occurrence, causes, and outcome of delirium in patients with advanced cancer: a prospective study. *Arch Intern Med*, 2000. 160(6): p. 786–94.
52. Fainsinger, R. and E. Bruera, Treatment of delirium in a terminally ill patient. *J Pain Symptom Manage*, 1992. 7(1): p. 54–6.
53. Lonergan, E., et al., Antipsychotics for delirium. *Cochrane Database Syst Rev*, 2007(2): p. CD005594.
54. Jackson, K.C. and A.G. Lipman, Drug therapy for delirium in terminally ill patients. *Cochrane Database Syst Rev*, 2004(2): p. CD004770.
55. Elsayem, A., et al., Subcutaneous olanzapine for hyperactive or mixed delirium in patients with advanced cancer: a preliminary study. *J Pain Symptom Manage*, 2010. 40(5): p. 774–82.
56. Leonard, M., et al., Reversibility of delirium in terminally ill patients and predictors of mortality. *Palliat Med*, 2008. 22(7): p. 848–54.
57. Chen, C.C., et al., Modified hospital elder life program: effects on abdominal surgery patients. *J Am Coll Surg*, 2011. 213(2): p. 245–52.
58. Siddiqi, N., et al., Interventions for preventing delirium in hospitalised patients. *Cochrane Database Syst Rev*, 2007(2): p. CD005563.